Research on Dry Immunisation Mechanisms
Dry syndrome is a chronic inflammation self-immunisation of the main excreta and excreta, and its immune mechanisms are complex and not yet fully defined.
In terms of genetic factors, studies have found that certain genes are closely related to the onset of dry syndrome. Specific subtypes in human white cell antigen genes, such as HLA-DR3, are significantly more frequent among patients than normal populations.
These genes can affect the process of identification and presentation of the organism ‘ s antigens, making it easier for the immune system to strike its own tissue in error. Moreover, genetic susceptibility can also be associated with the occurrence of disease by influencing the growth of immunocellular cells, their function and the expression of immunosuppressors. For cell immunisation, T-lymphocytes play a key role in the onset of dry syndrome. Among them, the imbalance of CD4+T-cell subgroups is an important link. The over-activation of the Th1 cell can lead to a large-scale inflammation of cell factors, such as jammer-gamma, which can cause inflammation. At the same time, the increase in the number and functioning of the th17 cells, whose secretive albino – 17-cell factors can recruit and activate neutral particles, further exacerbating the tissue damage.
In addition, the reduction in the number or functional impairment of modulated T-cells does not effectively inhibit the activation of their reactive T-cells, leading to the destruction of immunity. Vaccination of body fluids should also not be overlooked in the incidence mechanisms of dry syndrome. A wide range of self-antibodies can be detected in the patient, with high levels of specificity in anti-SSA and anti-SSB antibodies. These self-activated antibodies are the result of the abnormal activation of B lymphocytes. B-cells are stimulated by a number of factors, including antigen irritation, cell-factor effects, etc., and breed and divide, resulting in a large number of self-activated antibodies.
Moreover, B-cells can activate T-cells as an antigen-transmitting cell, creating a vicious circle that continues to drive the immune response. In the case of inflammation, there is an imbalance in the cytogen network. In addition to the above-mentioned jammer – gamma, white cell media – 17 etc., there is also a rise in the levels of tumour cause of death – alpha, among others. These cellular factors can act on excreta glands, such as saliva and tear glands, causing increased cartilage on the catheter, lymphocyte immersion on the gland, undermining the normal structure and functioning of the gland, leading to a decrease in the gland genre and typical symptoms of mouth and eye drying. In addition, the remedial system may be abnormally activated and involved in the process of organizational damage.
The following treatments are currently available:
(c) Improvement of oral drying symptoms: The use of artificial saliva, which simulates the composition and function of natural saliva, lubricates mouths, mitigates mouth drying. At the same time, patients must avoid taking drugs that reduce saliva, such as atropines. Attention should also be paid to oral hygiene and the prevention of tooth decay and oral infections.
Improving eye drying symptoms: Using artificial tear, it supplements the water to the eye and reduces its dryness and friction. Patients can also use humidifiers to increase the humidity of the surrounding environment and reduce the evaporation of tear.
Immunologically regulated treatment: Sugar-coated hormones, such as Pennison, are used when the disease is heavy and the body is affected by the symptoms of arthritis and inter-pulmonary disease. It can contain inflammation and mitigate tissue damage. However, long-term use can have side effects such as osteoporosis and increased blood sugar. Immunosuppressants, such as ammonium butterflies, sulfur, etc., are also used to regulate immune functions and to control progress, but indicators such as blood routines and liver and kidney functions are monitored during their use.
Biological agent treatment: The use of a biological agent may be considered for patients with poor conventional treatment. For example, the Letos stand alone, which can target a particular B cell, reduce the generation of its own antibody, thereby improving the condition, but at relatively high prices and with a possible risk of infection.
In the course of treatment, the patient is required to undergo regular re-diagnosis and the doctor adjusts the treatment to the changes in symptoms and the results of the examination.
In sum, the immunization mechanism for dry syndrome is the result of a multi-factor interaction, and in-depth studies help to develop more effective methods of diagnosis and treatment.
